Retinoic acid receptors and retinoid X receptor-alpha down-regulate the transforming growth factor-beta 1 promoter by antagonizing AP-1 activity.

Overexpression of the multifunctional growth factor transforming growth factor-beta 1 (TGF beta 1) has been connected to numerous diseases in human. TGF beta 1 expression is largely governed by three AP-1 binding sites located in two different promoters of this gene. We have examined the ability of retinoid receptors to inhibit the activity of the two promoters (especially the promoter 1) by cotransfection assays in the hepatocellular carcinoma cell line HepG2. When the TGF beta 1 promoter activity is induced by 12-O-tetradecanoyl phorbol13-acetate (an activator of AP-1-controlled gene transcription), this activity can be strongly repressed by retinoic acid receptor-alpha (RAR alpha), RAR beta, or retinoid X receptor-alpha (RXR alpha) as well as other members of the nuclear receptor family. Repression was hormone dependent and a function of receptor concentration. Heterodimerization of RAR alpha or RAR beta with RXR alpha did not modify the inhibition activities of these receptors, indicating that heterodimer formation is not required for antagonizing of AP-1 activity. On further examining the anti-AP-1 activity of RXR alpha we observed that three different AP-1-controlled promoters (TGF beta 1, collagenase, and cFos) can be inhibited. Using gel shift assays, we demonstrated that RXR alpha inhibits Jun and Fos DNA binding and that 9-cis RA enhances this inhibition, suggesting that a mechanism involving direct protein-protein interaction between RXR and AP-1 components mediates the inhibitory effect observed in vivo. Transfection analyses with RXR alpha point mutations revealed that residues L422, C432, and, to a lesser extent, residues L418 and L430, are involved in ligand-induced anti-AP1 activity of RXR alpha in vivo. Thus both types of retinoid receptors can inhibit AP-1-activated promoters, including the TGF beta 1 gene promoter, via a mechanism that involves protein-protein interaction.

[1]  K. Flanders,et al.  Interactions between retinoids and TGF beta s in mouse morphogenesis. , 1992, Development.

[2]  K. Umesono,et al.  Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling , 1992, Nature.

[3]  M. Pfahl,et al.  Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors , 1992, Nature.

[4]  Philippe Kastner,et al.  Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently , 1992, Cell.

[5]  C. Glass,et al.  RXRβ: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements , 1991, Cell.

[6]  R. Evans,et al.  Cross-coupling of signal transduction pathways: zinc finger meets leucine zipper. , 1991, Trends in genetics : TIG.

[7]  P. Scardino,et al.  Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. , 1991, Molecular endocrinology.

[8]  M. Nakajima,et al.  Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Karin,et al.  Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction , 1990, Cell.

[10]  Stephan Gebel,et al.  Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone , 1990, Cell.

[11]  S. Kliewer,et al.  Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor , 1990, Cell.

[12]  L J Peters,et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.

[13]  K. Yamamoto,et al.  Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. , 1990, Science.

[14]  E. Ruoslahti,et al.  Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. , 1990, The Journal of clinical investigation.

[15]  M. Sporn,et al.  Transactivation of the transforming growth factor beta 1 (TGF-beta 1) gene by human T lymphotropic virus type 1 tax: a potential mechanism for the increased production of TGF-beta 1 in adult T cell leukemia , 1990, The Journal of experimental medicine.

[16]  R. Evans,et al.  Nuclear receptor that identifies a novel retinoic acid response pathway , 1990, Nature.

[17]  M. Shago,et al.  Identification of a novel isoform of the retinoic acid receptor gamma expressed in the mouse embryo , 1990, Molecular and cellular biology.

[18]  P. Gruppuso,et al.  Transforming growth factor beta 1 in liver carcinogenesis: messenger RNA expression and growth effects. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  E. Appella,et al.  H-2RIIBP, a member of the nuclear hormone receptor superfamily that binds to both the regulatory element of major histocompatibility class I genes and the estrogen response element. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Chambon,et al.  Nuclear receptors enhance our understanding of transcription regulation. , 1988, Trends in genetics : TIG.

[21]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[22]  A. Schönthal,et al.  Requirement for fos gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters , 1988, Cell.

[23]  R. Tarone,et al.  Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. , 1988, The New England journal of medicine.

[24]  M. Sporn,et al.  Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. , 1988, The Journal of biological chemistry.

[25]  P. Chambon,et al.  Identification of a second human retinoic acid receptor , 1988, Nature.

[26]  V. Giguère,et al.  Identification of a receptor for the morphogen retinoic acid , 1987, Nature.

[27]  M. Karin,et al.  Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor , 1987, Cell.

[28]  H. Moses,et al.  Reversible inhibition of normal human prokeratinocyte proliferation by type beta transforming growth factor-growth inhibitor in serum-free medium. , 1986, Cancer research.

[29]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.

[30]  J. Mead,et al.  Effects of TGF-beta s in the liver: cell proliferation and fibrogenesis. , 1991, Ciba Foundation symposium.

[31]  M. Sporn,et al.  Transforming Growth Factor , 1990 .

[32]  J. Massagué,et al.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. , 1986, The Journal of biological chemistry.

[33]  M. Sporn,et al.  Increased secretion of type beta transforming growth factor accompanies viral transformation of cells , 1985, Molecular and cellular biology.